Do you approach the diagnosis and treatment of HIT patients differently in the outpatient setting or in a resource-limited community setting?  

For example, for outpatients or resource-limited settings with a moderate probability 4-T score (but low clinical suspicion), would you ever consider waiting for HIT testing before changing to nonheparinoid agent. Or would you switch a patient to immediately (to a DOAC or fondaparinux) given the risk?



Answer from: Medical Oncologist at Academic Institution